In serous ovarian cancers, strong CIP2A immunoreactivity correlated with worse prognosis (117), and the same was observed in a retrospective study on 152 ovarian cancer specimens, including serous, endometrioid, mucinous, and clear cell subtypes (118). The gene discussed is CIP2A; the disease is ovarian carcinoma.